Inside the filling machine, a caulk-like material used to integrate equipment from two different manufacturers was not easily cleanable — and appeared to be flaking. Drains running throughout the interior were never cleaned or monitored for microbial growth. Equipment documented as 'clean' tested above acceptance limits for residue. The Shilpa Medicare 483 reveals what happens when equipment design outpaces cleaning validation.
On November 21, 2025, FDA investigators issued a 483 to Shilpa Medicare Limited at their sterile injectable manufacturing facility in India. The first observation struck at the foundation of aseptic processing: “Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.” The specifics were worse than the headline suggested. Equipment used in the manufacture of sterile injectables was not composed of smooth, cleanable surfaces. Drains running throughout the inside of the equipment were never cleaned or monitored for microbial growth. And a caulk-like material used to integrate equipment from two different manufacturers was not easily cleanable — and appeared to be flaking.
The second observation reinforced the first. During a facility walkthrough on November 10, 2025, investigators found apparent residue on equipment interior surfaces near the duct. Swab sampling of the duct surface yielded results outside the acceptance criteria. The equipment had been documented as “clean.” A third observation found failures to thoroughly review unexplained discrepancies and batch failures — meaning that even when signals of process breakdown appeared in the data, the investigation system did not pursue them.
Taken together, the three observations describe a sterile manufacturing operation where the equipment itself was a contamination risk, the cleaning programme could not address surfaces that were never designed to be cleaned, and the quality system did not investigate the signals that this mismatch generated.
When equipment from two different manufacturers is integrated using caulk-like material inside an aseptic filling machine, the problem is not a cleaning failure. It is a design decision that made effective cleaning impossible.
21 CFR 211.63 requires that equipment used in the manufacture of drug products be of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance. 21 CFR 211.65 requires that equipment surfaces in contact with drug products shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product. 21 CFR 211.67 requires that equipment and utensils shall be cleaned, maintained, and sanitised at appropriate intervals to prevent malfunctions or contamination that would alter the drug product.
At Shilpa Medicare, the equipment failed all three requirements simultaneously. The filling machine used in sterile injectable manufacture contained drains running throughout its interior for removal of spray water used during cleaning. The inside of these drains were never cleaned or monitored for microbial growth. In aseptic processing, unmonitored drains inside production equipment represent an uncontrolled reservoir for microbial contamination — standing water, biofilm formation, and microbial proliferation in a space that is, by design, never subjected to cleaning or environmental monitoring.
The integration problem compounded the drain issue. The equipment used in manufacturing was sourced from one manufacturer, while the filling machine came from another. To integrate the two systems, a caulk-like material was used inside the aseptic equipment. This material was not easily cleanable and appeared to be flaking. Caulk-like materials in aseptic environments introduce two distinct risks: the material itself can harbour microbial contamination in surface irregularities that resist cleaning, and flaking material introduces particulate contamination directly into the product contact zone. Neither risk is manageable through cleaning procedure adjustments alone — the surface itself is the problem.
The equipment cleaning observation confirmed that these design deficiencies had operational consequences. Equipment documented as “clean” yielded swab results outside acceptance criteria. Under 21 CFR 211.67, equipment must be cleaned and maintained at appropriate intervals to prevent contamination. When the equipment has surfaces that cannot be effectively cleaned — drains that are never addressed, caulk that is flaking — the cleaning programme is operating against surfaces it was never validated to control. The batch discrepancy investigation failure completed the picture: signals of process breakdown were present in the data, but the quality system did not thoroughly review unexplained discrepancies or batch failures, whether or not the batch had already been distributed.
0
Drains running throughout the interior of the aseptic equipment were never cleaned or monitored for microbial growth — an uncontrolled reservoir inside the product contact zone.
0
The caulk-like integration material was not easily cleanable and appeared to be flaking — yet no assessment had evaluated whether the material was compatible with aseptic cleaning requirements.
Above Limits
Equipment documented as 'clean' yielded swab results outside acceptance criteria — confirming that the cleaning programme could not achieve its intended outcome on surfaces that were not designed to be cleaned.
The root cause is structural. When equipment procurement, equipment integration, cleaning validation, and environmental monitoring operate as independent programmes with independent ownership, no single function evaluates whether the equipment as-installed can actually be cleaned to aseptic standards. The gaps at Shilpa Medicare were not hidden. Drains are visible. Caulk is visible. Flaking is visible. But visibility does not create accountability when no system connects equipment design to cleaning validation.
Equipment procurement specifications focus on production capability — filling speed, dosing accuracy, throughput capacity. Cleaning validation is performed after installation, against the equipment as-received. When equipment from different manufacturers is integrated on-site, the integration materials and methods are evaluated for mechanical function but rarely for cleanability or compatibility with aseptic cleaning regimes. The caulk-like material at Shilpa Medicare was a solution to an integration problem. Nobody evaluated whether it was also a contamination problem.
Drains inside aseptic processing equipment exist for practical reasons — they remove water used during cleaning-in-place cycles. But drains are inherently difficult to clean, inspect, and monitor. They collect residual moisture, provide conditions for biofilm formation, and create harbourage sites that standard surface cleaning cannot reach. When these drains are never cleaned or monitored for microbial growth, the equipment contains a permanent, uncontrolled contamination source that operates beneath the cleaning programme's field of vision.
Standard cleaning validation protocols evaluate whether a defined cleaning procedure removes product residue and microbial contamination from product contact surfaces to below established limits. The underlying assumption is that all surfaces are cleanable — that the cleaning agent, contact time, and mechanical action can reach every relevant area. When equipment contains surfaces that are not smooth, not easily cleanable, or actively degrading (flaking caulk), the validation assumption is invalid. But most validation protocols do not include an explicit cleanability assessment of every surface within the equipment boundary.
The equipment at Shilpa Medicare was documented as 'clean' despite yielding swab results above acceptance criteria. This disconnect reveals a system where cleaning status is assigned based on procedure completion — the SOP was followed, the steps were executed, the record was signed — rather than verified against measured outcomes. When equipment surfaces cannot be effectively cleaned, completing the cleaning procedure and achieving clean equipment are two different things. The documentation system did not distinguish between them.
The drains were never cleaned. The caulk was never assessed. The equipment was labelled “clean.” When no system connects equipment design to cleaning capability, the cleaning programme validates a fiction.
Each comparison below addresses a specific failure documented in the Shilpa Medicare 483. The systemic approach does not add layers of manual review — it eliminates the structural disconnections that allowed non-cleanable surfaces, unmonitored drains, and false “clean” designations to coexist inside a sterile manufacturing operation.
Equipment is procured based on production specifications. Integration materials are selected for mechanical compatibility. Cleaning validation is performed after installation against the equipment as-received, without a prior assessment of whether all surfaces within the equipment boundary are smooth, non-porous, non-shedding, and accessible to the cleaning procedure. Caulk-like materials, inaccessible drains, and multi-vendor integration joints are inherited by the cleaning programme without evaluation.
Result: Cleaning validated against surfaces that cannot be cleaned
Every surface within the equipment boundary is assessed for cleanability before cleaning validation begins. Integration materials are evaluated against aseptic surface requirements — smooth, non-porous, non-shedding, compatible with cleaning agents. Drains and dead-legs are identified, mapped, and included in both the cleaning validation scope and the environmental monitoring programme. Equipment that contains non-cleanable surfaces is flagged before it enters the validation lifecycle, not after an inspector finds residue on it.
Result: Non-cleanable surfaces identified and addressed before validation
Environmental monitoring programmes in aseptic areas focus on air sampling, surface sampling of production contact surfaces, and personnel monitoring. Equipment-internal drains — designed for cleaning water removal — are excluded from both the cleaning programme and the environmental monitoring programme. No microbial sampling is performed inside drain channels. No cleaning cycle addresses drain interiors. The result is an unmonitored microbial reservoir inside aseptic equipment.
Result: Uncontrolled microbial reservoirs inside aseptic equipment
Drains and dead-legs within aseptic equipment are mapped as critical monitoring points in the contamination control strategy. Microbial sampling of drain interiors is performed at defined intervals. Cleaning protocols include specific steps for drain sanitisation with documented acceptance criteria. Trend data from drain monitoring feeds into the equipment risk assessment — enabling early detection of biofilm formation or microbial drift before it becomes a contamination event.
Result: Drain contamination detected and controlled proactively
Equipment is tagged as 'clean' when the cleaning procedure has been executed and documented — the SOP was followed, the steps were completed, the record was signed. Verification sampling is performed on a subset of surfaces, often the most accessible ones. Equipment containing surfaces that cannot be effectively cleaned still receives a 'clean' designation because the procedure was completed, even when the outcome was not achieved.
Result: 'Clean' equipment with residue above acceptance limits
Clean status assignment requires verified analytical results from all critical sampling points — including hard-to-clean areas identified during the cleanability assessment. The system cannot release equipment as 'clean' until results from every defined sampling location are within acceptance criteria. When results exceed limits, the system blocks release and triggers an investigation that includes equipment surface condition as a standard evaluation parameter.
Result: Clean status reflects actual equipment condition
Preventing the Shilpa Medicare pattern requires closing the gap between equipment design and cleaning capability — not through additional manual assessments, but by building cleanability into the equipment lifecycle from procurement through ongoing verification.
Automated health-based exposure limit calculations across every product-equipment combination, with worst-case matrix generation that accounts for equipment geometry, integration materials, drain locations, and surface characteristics. When equipment from multiple manufacturers is integrated, every interface — including integration materials, sealants, and connection points — is evaluated against cleanability criteria and included in the worst-case matrix. Sampling points target the surfaces where contamination actually accumulates, not the surfaces easiest to reach.
Equipment surface condition — including non-standard materials, integration joints, drain integrity, and evidence of degradation — is linked directly to cleaning validation status. When surface condition changes, affected cleaning validations are automatically flagged for reassessment. Material shedding, flaking, or degradation events trigger immediate investigation with cleaning validation impact as a mandatory evaluation parameter. The caulk-like material at Shilpa Medicare would have been flagged at the point of equipment integration, not discovered by an FDA inspector.
Cleaning outcomes are verified against measured analytical results at every critical surface, with trend analysis that detects drift before limits are breached. Environmental monitoring data from within and around equipment — including drains, dead-legs, and integration joints — feeds into the cleaning validation risk assessment. The system connects what the cleaning programme achieves to what the environmental monitoring programme detects, closing the gap that allowed unmonitored drains and false clean designations to coexist at Shilpa Medicare.
7+
CLEEN deployed across 7+ facilities at Zydus, delivering standardised HBEL-driven cleaning validation with automated worst-case matrix generation across the entire manufacturing network.
80%
Reduction in cleaning validation cycle time at Zydus — from weeks of manual worst-case calculations and protocol generation to automated, scientifically rigorous validation programmes.
100%
Complete elimination of manual calculation errors in HBEL computations and worst-case matrix generation — removing the human error factor from the most scientifically critical step in cleaning validation.
The objective is not more cleaning cycles or more monitoring points added to an existing programme. It is a fundamentally different relationship between equipment design, cleaning validation, and environmental monitoring — where the gaps documented at Shilpa Medicare are structurally impossible.
Conduct a systematic cleanability assessment of every surface within aseptic equipment boundaries — not just product contact surfaces, but integration joints, sealants, drains, dead-legs, and any non-standard materials introduced during equipment installation or modification. For each surface, evaluate: Is it smooth and non-porous? Is it accessible to the cleaning procedure? Is it included in the cleaning validation sampling plan? Is it monitored for microbial growth? The Shilpa Medicare 483 tells you exactly what the FDA will look for. Drains that are never cleaned. Integration materials that are flaking. Equipment documented as 'clean' with residue above limits. Map your current state against those findings before the FDA does it for you.
Replace static cleaning validation protocols with a system that connects equipment design data to cleaning validation scope. Every equipment modification, integration material, and non-standard surface must be captured in the cleaning validation risk assessment. Worst-case matrix generation must account for equipment-specific geometry, drain locations, and surface characteristics — not just product solubility and toxicological limits. Drains and dead-legs within aseptic equipment must be included in both the cleaning programme and the environmental monitoring programme with defined acceptance criteria and sampling frequencies. Clean status assignment must require verified analytical results from all critical surfaces, including hard-to-clean areas.
Validate the integrated cleaning programme under 21 CFR Part 11 requirements, with complete audit trails linking equipment design data, cleanability assessments, cleaning validation protocols, cleaning execution records, analytical results, and environmental monitoring data. Run challenge scenarios that mirror the Shilpa Medicare finding: process a cleaning cycle on equipment with complex geometry, drains, and integration joints, and verify that the system identifies all critical surfaces, monitors all relevant areas, and blocks clean status release when results are outside limits. Within two to three validation cycles, the data will demonstrate whether your programme controls contamination across the full equipment boundary — or only across the surfaces you chose to monitor.
Shilpa Medicare’s filling machine contained drains that were never cleaned, caulk that was flaking, and surfaces that could not be made smooth. The equipment was documented as “clean.” The question every quality leader running sterile manufacturing should ask: do we know what is inside our equipment — and can we actually clean it?
The Shilpa Medicare 483 is not a story about a cleaning failure. It is a story about an equipment design problem that the cleaning programme was never built to address. When a filling machine used for sterile injectables contains drains that are never cleaned or monitored, integration material that is flaking into the product zone, and surfaces that are not smooth or easily cleanable, the cleaning validation is operating against a physical reality it cannot control. Completing the cleaning procedure does not make the equipment clean. It makes the documentation say the equipment is clean.
This pattern — equipment design decisions that create non-cleanable surfaces, cleaning validation programmes that do not assess cleanability, and environmental monitoring programmes that exclude the areas of highest risk — is not unique to Shilpa Medicare. It is the structural outcome of treating equipment procurement, cleaning validation, and contamination control as separate programmes with separate ownership. When nobody owns the question “can this equipment actually be cleaned to aseptic standards,” the answer defaults to whatever the cleaning SOP produces, regardless of whether the outcome matches the documentation.
For quality leaders at sterile manufacturing facilities, the Shilpa Medicare finding is a prompt for a specific audit. Not a general cleaning review — a specific, surface-by-surface assessment of every piece of equipment in aseptic processing areas. Are there drains inside your equipment? Are they cleaned and monitored? Are there integration materials from multi-vendor equipment assemblies? Are those materials smooth, non-porous, and compatible with your cleaning regime? Has any material inside your equipment shown signs of degradation, flaking, or surface irregularity? Is equipment tagged as “clean” actually verified against analytical results at every critical surface? If any of these questions cannot be answered with documented evidence, the facility carries the same structural vulnerability that the FDA identified at Shilpa Medicare. The time to close the gap is before the inspection, not after.